These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3409242)

  • 1. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
    Hadidi AH; Coulter CE; Idle JR
    Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
    Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
    J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide metabolism in children.
    Yule SM; Boddy AV; Cole M; Price L; Wyllie R; Tasso MJ; Pearson AD; Idle JR
    Cancer Res; 1995 Feb; 55(4):803-9. PubMed ID: 7850793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
    Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
    Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites.
    Hadidi AH; Idle JR
    J Chromatogr; 1988 May; 427(1):121-30. PubMed ID: 3410892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
    Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
    Struck RF; Alberts DS
    Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
    Sladek NE; Doeden D; Powers JF; Krivit W
    Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
    Hemminki K
    Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
    Struck RF; Kirk MC; Witt MH; Laster WR
    Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
    Fetting JH; McCarthy LE; Borison HL; Colvin M
    Cancer Treat Rep; 1982 Aug; 66(8):1625-9. PubMed ID: 7105052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
    Chang TK; Waxman DJ
    Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro.
    Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP
    J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
    Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
    Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
    Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
    Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
    Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
    Hales BF
    Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.